JP7712867B2 - アセチル化ライター阻害剤の開発およびその使用 - Google Patents

アセチル化ライター阻害剤の開発およびその使用

Info

Publication number
JP7712867B2
JP7712867B2 JP2021523897A JP2021523897A JP7712867B2 JP 7712867 B2 JP7712867 B2 JP 7712867B2 JP 2021523897 A JP2021523897 A JP 2021523897A JP 2021523897 A JP2021523897 A JP 2021523897A JP 7712867 B2 JP7712867 B2 JP 7712867B2
Authority
JP
Japan
Prior art keywords
cancer
group
formula
bifunctional compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512900A5 (enExample
JP2022512900A (ja
Inventor
ジュン チィー，
アダム ディー． ダービン，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2022512900A publication Critical patent/JP2022512900A/ja
Publication of JP2022512900A5 publication Critical patent/JP2022512900A5/ja
Application granted granted Critical
Publication of JP7712867B2 publication Critical patent/JP7712867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
JP2021523897A 2018-11-02 2019-11-01 アセチル化ライター阻害剤の開発およびその使用 Active JP7712867B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754934P 2018-11-02 2018-11-02
US62/754,934 2018-11-02
PCT/US2019/059401 WO2020092907A1 (en) 2018-11-02 2019-11-01 Acetylation writer inhibitor development and uses thereof

Publications (3)

Publication Number Publication Date
JP2022512900A JP2022512900A (ja) 2022-02-07
JP2022512900A5 JP2022512900A5 (enExample) 2022-11-08
JP7712867B2 true JP7712867B2 (ja) 2025-07-24

Family

ID=70463920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523897A Active JP7712867B2 (ja) 2018-11-02 2019-11-01 アセチル化ライター阻害剤の開発およびその使用

Country Status (8)

Country Link
US (2) US12428412B2 (enExample)
EP (1) EP3873898B1 (enExample)
JP (1) JP7712867B2 (enExample)
CN (1) CN112969696B (enExample)
AU (1) AU2019371400B2 (enExample)
CA (1) CA3118597A1 (enExample)
ES (1) ES3038078T3 (enExample)
WO (1) WO2020092907A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111217802B (zh) * 2018-11-27 2021-10-08 海创药业股份有限公司 一类组蛋白乙酰化酶p300抑制剂及其用途
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
WO2020257278A2 (en) * 2019-06-18 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN116133692A (zh) 2020-07-30 2023-05-16 凯麦拉医疗公司 治疗突变淋巴瘤的方法
WO2022042707A1 (en) * 2020-08-27 2022-03-03 Cullgen (Shanghai) , Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
AU2022233431B2 (en) * 2021-03-09 2026-01-29 Dana-Farber Cancer Institute, Inc. Ep300 degrader and uses thereof in neuroblastoma
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
CN116375717B (zh) * 2021-12-30 2025-10-28 成都先导药物开发股份有限公司 螺环化合物及其双功能化合物和用途
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
GB202209404D0 (en) * 2022-06-27 2022-08-10 Univ Of Sussex Compounds
JP2025137900A (ja) * 2022-08-10 2025-09-25 住友ファーマ株式会社 第４級炭素で置換された３級アミド誘導体
JP2025524008A (ja) * 2022-09-07 2025-07-25 成都先導薬物開発股▲フン▼有限公司 スピロ化合物及びその用途
CN119255996B (zh) * 2022-09-08 2026-04-24 成都先导药物开发股份有限公司 螺环化合物及其用途
WO2024064358A1 (en) * 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR20250075705A (ko) 2022-10-07 2025-05-28 화이자 인코포레이티드 Hsd17b13 억제제 및/또는 분해제
EP4634169A1 (en) 2022-12-16 2025-10-22 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
CN116178339B (zh) * 2023-02-20 2024-08-06 杭州医学院 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用
GB202302941D0 (en) 2023-02-28 2023-04-12 Tocris Cookson Ltd Proteolysis-targeting chimeras
WO2025120592A1 (en) 2023-12-07 2025-06-12 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
KR20190084063A (ko) * 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020257278A2 (en) * 2019-06-18 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Michaelides, Michael R. 他，Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases，ACS Medicinal Chemistry Letters，2018年，9(1)，28-33

Also Published As

Publication number Publication date
US12428412B2 (en) 2025-09-30
WO2020092907A1 (en) 2020-05-07
US20220009916A1 (en) 2022-01-13
EP3873898A4 (en) 2022-11-30
EP3873898A1 (en) 2021-09-08
EP3873898B1 (en) 2025-05-28
US20250333402A1 (en) 2025-10-30
CN112969696B (zh) 2024-06-11
CN112969696A (zh) 2021-06-15
ES3038078T3 (en) 2025-10-09
AU2019371400A1 (en) 2021-04-08
AU2019371400B2 (en) 2024-10-17
JP2022512900A (ja) 2022-02-07
CA3118597A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7712867B2 (ja) アセチル化ライター阻害剤の開発およびその使用
US20250388562A1 (en) Small molecule degraders of helios and methods of use
US11530219B2 (en) Ligands to cereblon (CRBN)
US12234220B2 (en) Immunomodulatory compounds
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
US20220040317A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US20220047709A1 (en) Degraders of wee1 kinase
JP7626721B2 (ja) 小分子標的ブロモ／アセチルタンパク質およびその使用
CA3152306A1 (en) Selective hdac6 degraders and methods of use thereof
EP4054546A1 (en) Selective histone deacetylase (hdac) degraders and methods of use thereof
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US20220387604A1 (en) Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof
AU2022269564A1 (en) Class iia histone deacetylase (hdac) degrader ligands and methods of use thereof
HK40055968A (en) Histone acetylation writer inhibitor development and uses thereof
HK40055968B (en) Histone acetylation writer inhibitor development and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7712867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150